Our team acted as lead counsel for a large long-term care company named as a defendant in a False Claims Act (FCA) qui tam action involving allegations of medically unnecessary services and improper billing. After conducting an internal investigation, we successfully advocated that the allegations lacked merit, thus leading the Department of Justice and a State Attorney General’s Office to decline to intervene in the matter.
Successful Declination of Qui Tam for Long-Term Care Company
You Also May Be Interested In:
We represented BioScrip, Inc. in its merger with Option Care Enterprises, Inc. The newly combined company, Option Care Health, Inc., emerges as the largest independent home and alternate site infusion services provider in the United States. Option Care Health’s common stock will be listed on the Nasdaq Global Select Market under the ticker symbol BIOS.
Served as lead counsel to BriovaRx Infusion Services in obtaining a Certificate of Need to expand services in Middle Tennessee